BioSpace News Archive

Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, today announced that it will participate in a fireside chat during the H.C. Wainwright Virtual Global Life Sciences conference.

CTI BioPharma Corp. announced that the Compensation Committee of its Board of Directors granted equity awards to two new employees with a grant date of March 8, 2021, as equity inducement awards outside of the Company’s Amended and Restated 2017 Equity Incentive Plan and material to the employees’ acceptance of employment with the company.

Mesoblast Limited, global leader in allogeneic cellular medicines for inflammatory diseases, announced the successful completion and settlement of its US$110 million private placement led by a strategic US investor group, that was announced on Tuesday, March 2, 2021.

Gannex Pharma Co., Ltd., a wholly-owned company of Ascletis Pharma Inc., and Sagimet Biosciences Inc. jointly announced positive topline results from the China cohort of a Phase 2 randomized, placebo-controlled clinical trial of oral, once-daily fatty acid synthase inhibitor ASC40 that is being evaluated as a potential treatment for nonalcoholic steatohepatitis.

Orphazyme Announces the Global Brand Name for Arimoclomol – MIPLYFFA – Ahead of Prospective FDA and EMA Approvals Expanded its Early Access Program for NPC in the U.S. and Europe as Well as Expectation of European Regulatory Decision by Q4 2021

Axial Therapeutics Inc., today announced the appointment of A. Stewart Campbell, Ph.D. as Chief Executive Officer (CEO). Dr. Campbell will also serve as a member on the Axial Board of Directors.

NorthStar Medical Radioisotopes, LLC, a global innovator in the development, production and commercialization of radiopharmaceuticals used for medical imaging and therapeutic applications, and IBA (Ion Beam Applications S.A., EURONEXT), the world’s leading provider of proton therapy solutions for the treatment of cancer, today announced a collaboration to increase global availability of technetium-99m (Tc-99m)

Business leaders and community organizations have joined forces to support R.E.S.T., “Reopening Effectively and Safely Together”, a multi-state mission and initiative created and designed to address the tough challenges ahead as we look forward to the post-COVID-19 world.

– Exelixis has exclusive license to panel of monoclonal antibodies against an undisclosed oncology target for biologics applications, leveraging WuXi Biologics integrated technology platforms – – In addition to a modest upfront payment, WuXi Biologics is eligible for potential milestones and royalties on net sales of potential products –

ABU DHABI, United Arab Emirates--( BUSINESS WIRE )-- Technology Innovation Institute (TII), the applied research pillar of Abu Dhabi’s Advanced Technology Research Council (ATRC), today announced the appointment of international experts in the field of systems security to the Board of Advisors of its Secure Systems Research Centre (SSRC). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/202103080